| B -FarmL-D | ATK 8946 |
| STT koodi: | 10832 |
| B -Varfa-D | KL 6343 |
| B -SLCO1B1 | KL 6344 |
| B -CYP2D6 | KL 6345 |
| B -CYP2C19 | KL 6346 |
The method is accredited in accordance with the quality management system of the place of occurrence (see below).
B -SLCO1B1 is available as a separate study in our subcontracted laboratory. Other substudies are not carried out separately.
The study covers 29 genes and includes a statement on the dosing of more than 100 drugs according to the patient's phenotype. The statement is intended for use by general practitioners or specialists.
Pharmacogenetics (PGx) refers to the field of science that studies genetic variations that have an effect on the metabolism of pharmaceutical substances and their effects in the body.
With the help of the pharmacogenetic test, it is possible to predict and take into account the individual characteristics of the patient when choosing medicines and planning their dosage. With careful planning, avoiding harmful side effects or insufficient drug response becomes possible.
The B -FarmL-D test panel examines at least 29 genes affecting drug metabolism, the variations of which affect the metabolism of commonly prescribed drugs. New genes are added to the test panel as recommended by CPIC®.
Planning and initiation of drug treatment, determination of dosage, prevention of harmful side effects and interactions, suspicion of insufficient efficacy or adverse effects of drug treatment.
3 ml of EDTA blood.
The mobile phone number of the patient or his guardian can be given as additional information for the examination, so the patient can easily get the examination result for own use.
EDTA tube
The sample can be stored for 24 hours at room temperature. Short-term (1-5 days) storage in the refrigerator. Long-term storage (more than 5 days) frozen.
The research is done with TaqMan chemistry (SNP variations with OpenArray technology and CYP2D6 gene amplification/deficiency with TaqManMGB chemistry). The test panel examines known variations. The study does not detect rare variations of the studied genes or possible rare structural variants of the CYP2D6 gene.
ABCB1 digoxin, ondansetron
ABCG2 allopurinol, atorvastatin, rosuvastatin
ALDH2 alcohol, glyceryl trinitrate
BCHE mivacurium, suxamethone, tetracaine
CACNA1S desflurane, enflurane, halothane, isoflurane, methoxyflurane, sevoflurane, succamethone
CYP1A2 agomelatine, caffeine, clozapine, olanzapine, paroxetine, rucaparib
CYP2B6 bupropion, efavirenz, methadone, nevirapine, prasugrel
CYP2C_rs12777823 warfarin
CYP2C19 amitriptyline, brivaracetam, citalopram, clopidogrel, escitalopram, fluoxetine, fluvoxamine, imipramine, lansoprazole, mephenytoin, omeprazole, pantoprazole, phenytoin, sertraline, voriconazole
CYP2C8 to pioglitazone, rosiglitazone
CYP2C9 acenocoumarol, diclofenac, dronabinol, ibuprofen, irbesartan, losartan, meloxicam, phenytoin, pioglitazone, tolbutamide, warfarin
CYP2D6 amitriptyline, atomoxetine, codeine, desipramine, dextromethorphan, duloxetine, haloperidol, metoprolol, nortriptyline, ondansetron, oxycodone, paroxetine, risperidone, tamoxifen, tramadol
CYP3A4 atorvastatin, simvastatin
CYP3A5 prasugrel, tacrolimus, vincristine
CYP4F2 warfarin
DPYD capecitabine, flucytosine, fluorouracil, tegafur
F2 (prothrombin) avatrombopag, conjugated estrogens, eltrombopag, estradiol, estriol, ethinylestradiol, lusutrombopag, romiplostim, tamoxifen, tibolone
F5 avatrombopag, conjugated estrogens, eltrombopag, estradiol, estriol, ethinylestradiol, lusutrombopag, romiplostim, tamoxifen, tibolone
G6PD articaine, ascorbic acid, bupivacaine, chlorprocaine, chloroquine, chlorpropamide, ciprofloxacin, dabrafenib, dapsone, flutamide, hydroxychloroquine, levofloxacin, lidocaine, mafenide, maphenhydramine, metoclopramide, nitrofurantoin, norfloxacin, pegloticase, prilocaine, primaquine, probenecid, quinine, rasburicase, ropivacaine , sodium nitrite, sulfadiazine, sulfamethoxazole, sulfasalazine, sulfisoxazole, tafenoquine, tetracaine, tolbutamide
GRIK4 citalopram, escitalopram
IFNL3 boceprevir, daclatasvir, peginterferon alfa-2a, peginterferon alfa-2b, ribavirin, simeprevir, sofosbuvir, telaprevir
MTHFR folic acid, methotrexate
NAT2 amifampridine, dapsone, hydralazine, isoniazid, sulfamethoxazole, sulfasalazine
NFIB clozapine
NUDT15 azathioprine, mercaptopurine, thioguanine
SLCO1B1 atorvastatin, fluvastatin, lovastatin, methotrexate, pitavastatin, pravastatin, rosuvastatin, simvastatin
TPMT azathioprine, cisplatin, mercaptopurine, thioguanine
UGT1A1 arformoterol, atazanavir, belinostat, binimetinib, cabotegravir, dolutegravir, erlotinib, govitecan, indacaterol, irinotecan, nilotinib, patisiran, raltegravir, sasatuzumab govitecan
VKORC1 warfarin
21
A statement with recommendations for the selection and dosing of more than 100 drugs.
The statement is prepared by SYNLAB's partner Abomics Oy, a specialist in pharmacogenetics. Abomics uses the GeneRx database, containing compiled information from multiple sources about the influence of genes on the efficacy and safety of drugs, including drug-specific phenotype-specific recommendations with dosage instructions.
The results of the test can be easily viewed by the patient through the Geenitaltio service portail. For this, it is highly recommended that the patient informs his mobile phone number to be added to the background information of the study. This is not mandatory, but in this case, the patient does not receive Geenitaltio service credentials.
More information: www.abomics.fi
The result of this examination is automatically saved in the patient portal Geenitaltio,
a personal repository for genetic test results.
When ordering the study, a mobile phone number should be asked from the patient for the preliminary study information. When the requested Pharmacogenetic test has been completed, the result will be sent to the Electronic health record portal, using normal response traffic system. In addition, the result with interpretations is stored in the Geenitaltio patient portal service. The patient receives a message on his phone from the recording, with instructions for logging into the system. The results in the Geenitaltio can be used by the patient if necessary.
The patient can refuse to give his phone number if he wishes, but in that case he will not receive a message about the completion of the results.
The test concern only genes related to drug safety, not disease risk genes, for example. The patient cannot be identified from this study, as in the whole genome sequencing.
Abomics GeneRx -database: https://generx.fi/ https://generx.fi/tietoa.html
Duodecim: Terveysportti Farmakogenetiikka
Duodecim: Farmakogeneettiset testit lääkehoidon tukena (Duodecim)
Depressio. Käypä hoito -suositus. Suomalaisen
Lääkäriseuran Duodecimin ja Suomen Psykiatriyhdistys ry:n asettama työryhmä.
Helsinki: Suomalainen Lääkäriseura Duodecim, 2023 (Julkaistu: 03.04.2023). https://www.kaypahoito.fi/hoi50023
Lääkkeiden haitta- ja yhteisvaikutukset, lääkeaineiden pitoisuusmittaukset ja CYP-genotyyppien määrittäminen. Käypä hoito -suositus. Suomalaisen Lääkäriseuran Duodecimin ja Suomen
Psykiatriyhdistys ry:n asettama työryhmä. Helsinki: Suomalainen Lääkäriseura Duodecim, 2022 (julkaistu 8.1.2020). Päivitetty 3.4.2023
SYNLAB Tallinna
Accreditation: EAK (EA jäsen)
Standard: EVS-EN ISO 15189
Service center for professionals: ammattilaisneuvonta@synlab.fi
Expert contact in Abomics Oy: info@abomics.fi